A Phase 2 interventional study of Letermovir oral granules and Letermovir tablet in Cytomegalovirus (CMV) Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 40 sites in 11 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 10th largest by enrollment, is one of 4 that started in 2019, is one of 4 in phase 2, and was the 3rd registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
Elisabeth Kincaide · Sites in United States
Ages 18+
Hospital do Rim e Hipertensão
Ages 18+
By country, each count listing its studies:
letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2019.
This study's enrollment of 65 is close to the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies testing letermovir in Cytomegalovirus Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407232Phase 3University of Wisconsin, MadisonLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | 2027-08 |
| NCT06334497Phase 3Assistance Publique - Hôpitaux de ParisLetermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections | 2027-09 |
| NCT06066957University of PennsylvaniaOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | 2026-12-15 |
| NCT06057194Maimónides Biomedical Research Institute of CórdobaEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to \<18 years of age (adolescents); Age Group 2: From 2 to \<12 years of age (children); and Age Group 3: From birth to \<2 years of age (neonates, infants and toddlers). All participants will receive open label LET for 14 weeks (\~100 days) post-transplant, with doses based on body weight and age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Drug: Letermovir oral granules · Drug: Letermovir tablet · Drug: Letermovir intravenous
Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Also known as: MK-8228, AIC246, AIC001
Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Also known as: MK-8228, AIC246, AIC001
Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Also known as: MK-8228, AIC246, AIC001
Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Maximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Minimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: 24 hours post-dose
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
Time frame: Day 7: 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Concentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model .Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: 24 hours post-dose
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
Time frame: Day 7: 24 hours post-dose
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure type is Geometric Mean, and a measure of dispersion is not determined when N \<2.
Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Ctrough of Plasma Letermovir Taken During Sparse PK for Oral Formulation
Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir during sparse PK for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.
Time frame: Day 7: 24 hours post-dose
Ctrough of Plasma Letermovir Taken During Sparse PK as IV Formulation
Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation during sparse PK. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.
Time frame: Day 7: 24 hours post-dose
Percentage of Participants With One or More Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% confidence interval (CI) is based on the exact binomial method proposed by Clopper and Pearson.
Time frame: Up to Week 48 post-transplant (up to 52 weeks)
Percentage of Participants Who Discontinued Study Medication Due to an AE.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% CI is based on the exact binomial method proposed by Clopper and Pearson.
Time frame: Up to Week 14 post-transplant (up to 18 weeks)
Percentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant
Clinically significant cytomegalovirus (CMV) infection is defined as CMV end organ disease (proven or probable) or initiation of pre-emptive therapy (PET) based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 14 post-transplant visit window.
Time frame: Up to Week 14 post-transplant (up to 18 weeks)
Percentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant
Clinically significant CMV infection is defined as CMV end organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 24 post-transplant visit window.
Time frame: Up to Week 24 post-transplant (up to 28 weeks)
Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the First Day of Administration of Oral Formulation
Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.
Time frame: Day 1 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)
Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the Eighth Day of Administration of Oral Formulation
Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.
Time frame: Day 8 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)
Male and female recipients of a first allogeneic hematopoietic stem cell transplant (HSCT), between the ages of birth and \<18 years of age, who were at risk for cytomegalovirus (CMV) infection and/or disease, and who had undetectable CMV deoxyribonucleic acid (DNA) collected within 5 days before enrollment. were enrolled in this study.
| Milestone | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Started | 28 | 29 | 8 |
| Treated | 28 | 27 | 8 |
| Completed | 21 | 21 | 6 |
| Not completed | 7 | 8 | 2 |
| Withdrew: Death | 3 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 3 | 4 | 1 |
| Withdrew: Not treated | 0 | 2 | 0 |
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years | 80300 ± 74.9 | 62900 ± 37.4 | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years | — | 39500 (23900 to 65200) | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years | — | — | 26200 |
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Maximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years | 7410 ± 70.1 | 10800 ± 17.4 | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Cmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years | — | 5500 (5430 to 5580) | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Cmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years | — | — | 2950 |
Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Minimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years | 845 ± 107.5 | 171 ± 2046.8 | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years | — | 481 (207 to 1120) | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years | — | — | 61.7 |
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years | 114000 ± 37.8 | — | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years, ≥30 kg BW | 2 - <12 Years, 18 to <30 kg BW | Birth - <2 Years |
|---|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years | — | 36200 (21000 to 62100) | 31500 (20300 to 48900) | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years | — | 25300 | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
| hr*ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years | — | — | 37300 |
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model .Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Concentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years | 30600 ± 16.4 | — | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years, ≥30 kg BW | 2 - <12 Years, 18 to <30 kg BW | Birth - <2 Years |
|---|---|---|---|---|
| Ceoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years | — | 16800 (14900 to 19000) | 8200 (7580 to 8870) | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ceoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years | — | 8630 | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ceoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years | — | — | 11700 |
Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years | 709 ± 256.8 | — | — |
Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.
| ng/mL | 12 - <18 Years | 2 - <12 Years, ≥30 kg BW | 2 - <12 Years,18 to <30 kg BW | Birth - <2 Years |
|---|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years | — | 71.6 (12.9 to 397) | 318 (134 to 754) | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years | — | 216 | — |
Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure type is Geometric Mean, and a measure of dispersion is not determined when N \<2.
| ng/mL | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Ctrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years | — | — | 98.3 |
Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir during sparse PK for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.
No measurements were reported for this outcome.
Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation during sparse PK. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% confidence interval (CI) is based on the exact binomial method proposed by Clopper and Pearson.
| Percentage of participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Percentage of Participants With One or More Adverse Event (AE) | 100.0 (87.7 to 100.0) | 100.0 (87.7 to 100.0) | 100.0 (63.1 to 100.0) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% CI is based on the exact binomial method proposed by Clopper and Pearson.
| Percentage of participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Percentage of Participants Who Discontinued Study Medication Due to an AE. | 17.9 (6.1 to 36.9) | 7.4 (0.9 to 24.3) | 12.5 (0.3 to 52.7) |
Clinically significant cytomegalovirus (CMV) infection is defined as CMV end organ disease (proven or probable) or initiation of pre-emptive therapy (PET) based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 14 post-transplant visit window.
| Percentage of participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Percentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant | 20.0 (6.8 to 40.7) | 16.7 (4.7 to 37.4) | 28.5 (3.7 to 71.0) |
Clinically significant CMV infection is defined as CMV end organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 24 post-transplant visit window.
| Percentage of participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Percentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant | 24.0 (9.4 to 45.1) | 25.0 (9.8 to 46.7) | 28.6 (3.7 to 71.0) |
Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.
| Participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Very good | 0 | 3 | 0 |
| Good | 1 | 5 | 3 |
| Neither good nor bad | 1 | 8 | 1 |
| Bad | 1 | 8 | 3 |
| Very bad | 1 | 3 | 0 |
Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.
| Participants | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years |
|---|---|---|---|
| Very good | 0 | 3 | 0 |
| Good | 1 | 4 | 3 |
| Neither good nor bad | 1 | 8 | 4 |
| Bad | 0 | 5 | 0 |
| Very bad | 0 | 3 | 0 |
Collected over All-cause mortality (ACM): from allocation/randomization (i.e. prior to treatment) up to Week 48 post-transplant (up to 52 weeks). AEs: From first treatment up to Week 48 post-transplant (up to 52 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 - <18 Years | 4/28 (14.3%) | 13/28 (46.4%) | 27/28 (96.4%) |
| 2 - <12 Years | 2/29 (6.9%) | 18/27 (66.7%) | 27/27 (100%) |
| <2 Years | 0/8 (0%) | 7/8 (87.5%) | 8/8 (100%) |
| Event | 12 - <18 Years | 2 - <12 Years | <2 Years |
|---|---|---|---|
| Epstein-Barr virus infection reactivationInfections and infestations | 0/28 | 0/27 | 2/8 |
| Secondary adrenocortical insufficiencyEndocrine disorders | 0/28 | 0/27 | 1/8 |
| Acute graft versus host diseaseImmune system disorders | 0/28 | 0/27 | 1/8 |
| Graft versus host diseaseImmune system disorders | 1/28 | 1/27 | 1/8 |
| BacteraemiaInfections and infestations | 0/28 | 1/27 | 1/8 |
| Cytomegalovirus infection reactivationInfections and infestations | 1/28 | 0/27 | 1/8 |
| Device related infectionInfections and infestations | 0/28 | 0/27 | 1/8 |
| Epstein-Barr virus test positiveInvestigations | 0/28 | 0/27 | 1/8 |
| NeurotoxicityNervous system disorders | 0/28 | 0/27 | 1/8 |
| Venoocclusive diseaseVascular disorders | 0/28 | 0/27 | 1/8 |
| Event | 12 - <18 Years | 2 - <12 Years | <2 Years |
|---|---|---|---|
| VomitingGastrointestinal disorders | 17/28 | 21/27 | 4/8 |
| DiarrhoeaGastrointestinal disorders | 14/28 | 13/27 | 1/8 |
| PyrexiaGeneral disorders | 11/28 | 13/27 | 4/8 |
| NauseaGastrointestinal disorders | 12/28 | 8/27 | 0/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/28 | 11/27 | 0/8 |
| Abdominal painGastrointestinal disorders | 11/28 | 7/27 | 1/8 |
| Graft versus host diseaseImmune system disorders | 10/28 | 10/27 | 3/8 |
| HypertensionVascular disorders | 8/28 | 10/27 | 0/8 |
| NeutropeniaBlood and lymphatic system disorders | 2/28 | 9/27 | 1/8 |
| StomatitisGastrointestinal disorders | 9/28 | 9/27 | 0/8 |
Treated Participants
| Age, Continuous(Years) | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years | Total |
|---|---|---|---|---|
| Mean | 14.1 ± 1.5 | 6.6 ± 3.2 | 0.7 ± 0.3 | 9.1 ± 5.3 |
| Sex: Female, Male(Participants) | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years | Total |
|---|---|---|---|---|
| Female | 13 | 5 | 1 | 19 |
| Male | 15 | 22 | 7 | 44 |
| Ethnicity (NIH/OMB)(Participants) | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 4 | 1 | 14 |
| Not Hispanic or Latino | 14 | 21 | 6 | 41 |
| Unknown or Not Reported | 5 | 2 | 1 | 8 |
| Race (NIH/OMB)(Participants) | 12 - <18 Years | 2 - <12 Years | Birth - <2 Years | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 3 | 0 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 0 | 3 |
| White | 15 | 22 | 7 | 44 |
| More than one race | 4 | 2 | 1 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2019 to primary completion in Jan 2023, 40 months.
Results were first posted in Jan 2024, 1 year after primary completion.
Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 62. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir